Tuesday, February 26, 2013

Hormone Therapy Blocks Accelerated Biological Aging Seen In Women With Alzheimer's Risk Factor

Dr. Enrique Jacome
Healthy menopausal women carrying a well-known genetic risk factor for Alzheimer's disease showed measurable signs of accelerated biological aging, a new study has found. 

However, in carriers who started hormone therapy at menopause and remained on that therapy, this acceleration was absent, the researchers said. Hormone therapy for non-carriers of the risk factor, a gene variant called ApoE4, had no protective effect on their biological aging. 

"This shows that ApoE4 is contributing to aging at the cellular level well before any outward symptoms of decline become apparent," said Natalie Rasgon, MD, PhD, professor of psychiatry and behavioral sciences at the Stanford University School of Medicine and director of the Stanford Center for Neuroscience in Women's Health. "Yet, estrogen appears to have a protective effect for middle-aged women who are carrying this genetic risk factor." 

All people carry two copies of a gene called ApoE. (One copy is inherited from each parent). Like genes for eye or hair color, ApoE comes in more than one version. Some 15 to 20 percent of Americans carry at least one copy of ApoE4, a version that puts them at substantially increased risk for late-onset Alzheimer's disease in comparison with people who are not ApoE4 carriers. 

Rasgon is the senior author of a study involving 70 relatively well-educated, high-functioning women. It will be published online in PLOS ONE. First author Emily Jacobs, PhD, is a postdoctoral fellow at Harvard Medical School. When the work took place, Jacobs was associated with the lab of another study co-author, Elissa Epel, PhD, associate professor of psychiatry at the University of California-San Francisco. 

"We know from numerous studies that ApoE4 is a major genetic risk factor for cognitive decline, Alzheimer's disease and early mortality," Jacobs said. "We wanted to see whether an accelerated rate of biological aging explained this risk." 

Another co-author of the study is Elizabeth Blackburn, PhD, professor of biochemistry and biophysics at UCSF, who won the Nobel Prize in 2009 for her work elucidating the mechanism by which intracellular features called telomeres act as biological clocks. 

Telomeres are repeated sequences of alternating chemical units of DNA that cap the ends of each chromosome in every cell of all living creatures from fungi to humans. Their function is analogous to that of the plastic caps ringing the ends of a shoelace: They stabilize chromosomes, keeping them from unraveling and preventing other damage, too. But telomeres themselves are not perfectly stable. The process of cell division, as well as bouts of oxidative stress or inflammation, cause them to shorten. If they reach a point at which chromosomal integrity is challenged, this could give rise to cancer or other malfunction in the cell housing the challenged chromosomes. Evolution has engineered protective mechanisms into such cells so that they die or, at least, lose their ability to divide further. But this evolutionary emergency brake has its downside: It contributes to the slow but steady deterioration that manifests visibly in our aging skin and, less visibly, in all the other bodily organs. 

Using telomere shortening as an index of biological aging, the investigators drew blood samples from almost 70 healthy women, most of them between the ages of 45 and 65, who had been on hormone therapy since menopause. These women were randomly divided into two groups. One group remained on hormones, while the second group discontinued therapy. 

Blood samples from the volunteers were taken when they first entered the study and again two years later. Jacobs, Rasgon and their colleagues separated white blood cells from each sample, extracted the cells' DNA and measured the length of each woman's telomeres at both time points. Then they calculated the change in telomere length that had taken place over the two-year period. 

"Telomere length is relatively easy to measure in blood cells, and it's an emerging marker of biological aging," said Jacobs. "It predicts the incidence of age-related diseases and mortality." 

Among the many other assessments the researchers made on these women was their ApoE status. They found that ApoE4 carriers' telomeres were six times as likely as those of non-carriers to undergo significant shortening within the two-year study window. On average, the telomeres of ApoE4 carriers had shortened by an amount equivalent to what might be expected to take a decade, based on other studies of healthy women. 

However, hormone therapy effectively zeroed out ApoE4's negative influence on telomere length over time. Carriers who remained on this regimen showed no evidence of telomere shortening. 

"Our take-home findings from this study were, first, that ApoE4 carriers are at greater risk of biological aging, which is associated with negative health outcomes and, second, that if you were a postmenopausal ApoE4 carrier, being on estrogen therapy was a good thing for telomere length, an established measure of biological aging at the cellular level," Rasgon said. "This brings us a step closer to being able to identify which women will benefit the most from estrogen replacement therapy." 

In 2002, one arm of a large-scale longitudinal trial of women examining hormone therapy was halted due to an unexpected increase in adverse cardiovascular events among women on the therapy. The ensuing publicity resulted in women abandoning the regimen in droves. But the trial subjects among whom these ill effects occurred were women who had begun estrogen treatment years after reaching menopause. Subsequent studies have demonstrated that women who start treatment at menopause or soon afterward may experience some benefit. 

Rasgon noted that in addition to timing and ApoE status, the type of estrogen formulation used may prove to be an important determinant of hormone therapy's health impact. She said she expects to publish other work soon concerning the differential effects of different formulations.


www.vivenaturalhormones.com

Tuesday, January 29, 2013

Studies Suggest Testosterone Replacement Therapy Improves Risk Factors For Cardiovascular Disease And Diabetes

Dr. Enrique Jacome
Testosterone deficiency becomes more common with age, occurring in 18 percent of 70-year-olds, said a coauthor of both studies, Farid Saad, PhD, of Berlin-headquartered Bayer Schering Pharma. Low testosterone levels are linked to the metabolic syndrome--a cluster of metabolic risk factors that increase the chances of developing heart disease, stroke, and type 2 diabetes--and other health problems, including loss of bone and muscle mass, depression, and decreased libido.


Saad's research showed that restoring testosterone to normal levels in hypogonadal, or testosterone-deficient, men led to major and progressive improvements in features of the metabolic syndrome. Furthermore, men older than 63 benefited as much as younger men, they found. Treatment lasted a year and used a slow-release, injectable form of the hormone (testosterone undecanoate) that is not yet available in the United States.
All 95 men in the studies (ages 34 to 69 years) had the metabolic syndrome. To receive this diagnosis, patients must have three of the following five risk factors: increased waist circumference (abdominal fat), low HDL ("good") cholesterol, high triglycerides (fats in the blood), high blood pressure, and high blood sugar.
The first study showed that testosterone treatment significantly reduced waist circumference, total cholesterol, LDL ("bad") cholesterol, triglycerides, and body mass index (a measure of body fat). Treatment also increased "good" cholesterol. Improvements were progressive over 12 months, indicating that benefits may continue past a year, Saad said.
In the second study, the researchers divided the patient population into three groups by age: less than 57 years, 57 to 63 years, and more than 63 years. They found that the oldest men had similar improvements in metabolic risk factors to the youngest men.
Additionally, the investigators looked at the degree of testosterone deficiency before treatment. This beginning level of testosterone deficiency did not predict the beneficial outcome, they found. Men whose subnormal testosterone levels were not as low as the others had similar improvements in metabolic risk factors to men with the lowest levels, according to Saad.
"We conclude that if elderly men have a deficiency of testosterone, it is worthwhile to treat them with testosterone," he said.
Researchers from The Netherlands and Germany collaborated on these studies. Study participants received treatment in a hospital clinic in Bremerhaven, Germany, which provided free care and testosterone through the German social health care system.
Disclosure: Bayer Schering makes a brand of testosterone undecanoate. Saad is an employee of Bayer Schering and contributed to the study design, he reported.

Monday, January 7, 2013

Healthy Lifestyle During Menopause May Decrease Breast Cancer Risk Later

Dr. Enrique Jacome
Obese, postmenopausal women are at greater risk for developing breast cancer and their cancers tend to be more aggressive than those in lean counterparts. A University of Colorado Cancer Center study published in the December issue of the journal Cancer Research shows how this risk might be prevented. 

"By using nutrient tracers for fat and sugar, we tracked where the body stored excess calories. In lean models, excess fat and glucose were taken up by the liver, mammary and skeletal tissues. In obese models, excess fat and glucose were taken up by tumors, fueling their growth," says Erin Giles, PhD, postdoctoral researcher at the CU Cancer Center and the paper's lead author. 

In short, if you are lean, excess calories go to healthy tissue. If you are obese, excess calories feed the tumor. 

"This implies that the menopausal window may be an opportunity for women to control their breast cancer risk through weight management," Giles says. 

In this study, Giles worked with a team of scientists including postdoctoral fellows Elizabeth Wellberg and Sonali Jindal, as well as faculty members Steve Anderson, Pepper Schedin, Ann Thor and Paul Maclean. Their study also showed that tumors from obese animals had increased levels of the progesterone receptor, and this receptor appears to give tumors a metabolic advantage for growth. To extend their findings to humans, they recruited gene analysis experts David Astling and Aik-Choon Tan who analyzed 585 human breast cancers and found that human tumors expressing the progesterone receptor had the same metabolic advantage. 

"Basically, we saw an abnormal metabolic response to fat and sugar in the obese that, in many ways, mirrors the response to fat and sugar in Type II diabetes," Giles says. Noticing this similarity, the group tested the use of the common Type II diabetes drug, Metformin, in their model of postmenopausal breast cancer. 

"With treatment, tumor size was dramatically decreased in the obese, and tumors showed reduced expression of the progesterone receptor," Giles says. 

Using a pre-clinical model, the investigators found that weight gain during menopause is particularly bad for those who are obese when entering menopause. Together, the results of this study suggest that the combination of obesity and weight gain during menopause can impact breast cancer in two ways. First, tumors that arise in obese women appear to have a metabolic advantage, and second, the inability to store excess calories in healthy tissues may further fuel tumor growth. 

"While drugs may be useful in controlling breast cancer risk in obese, postmenopausal women, our results imply that a combination of diet and exercise may be equally if not more beneficial," Giles says. 

The group's ongoing studies are testing whether interventions such as diet and exercise, during the period of menopausal weight gain, can improve tumor outcomes. 


www.vivenaturalhormones.com

Friday, December 28, 2012

How To Recognize The Symptoms Of Menopause

Dr. Enrique Jacome
Menopause and perimenopause can wreak havoc on your hormones and that can cause a plethora of symptoms. The symptoms of menopause and perimenopause can have a drastic effect on your life, but you don't have to live with them! By attaining a proper hormone balance, you can take your life back and feel much better.

All of a woman's hormones must work in harmony with one another for the body to function optimally. So, even when only one unbalanced hormone is present, it will adversely affect all the others and may result in any of several menopausal symptoms, including:


  • Hot Flashes
  • Night Sweats
  • Weight Gain
  • Insomnia
  • Fatigue
  • Low Libido
  • Vaginal Dryness
  • PMS
  • Mood Swings
  • Irritability
  • Depression
  • Endometriosis
  • Fibrosis
  • Foggy Memory










That beautiful, tuned melody that we look for is your optimal health, free from symptoms of perimenopause, menopause and thyroid imbalance. Women with balanced hormones integrated with proper nutrition and fitness can have a better quality of life as they age. 

If you are experiencing these menopause symptoms, we can help you to get tested and discover your current hormone levels. Once we know your results, we can find that beautiful melody and relieve you from the symptoms that have been haunting you. You will be healthier, happier, and free to enjoy your life without the inconvenience and frustration of these troubling symptoms.

Contact us at (760) 203-5751 to schedule an appointment and learn more about how hormone therapy can bring about a healthier, younger you
.

www.vivenaturalhormones.com

Monday, December 3, 2012

Study Finds Testosterone Replacement Therapy Improves Symptoms Of Metabolic Syndrome

Dr. Enrique Jacome
Hormone replacement therapy significantly improved symptoms of metabolic syndrome associated with testosterone deficiency in men, a new study from Germany finds. The results was presented over the Summer at The Endocrine Society's 94th Annual Meeting in Houston.
Metabolic syndrome comprises a cluster of complications that can increase the risk of heart and blood-vessel disease as well as type 2 diabetes. These complications include excess body weight, especially around the waist and torso, and abnormal concentrations of fat in the blood, known as lipids. In particular, patients with metabolic syndrome have high blood levels of the so-called bad fats, or triglycerides and low-density lipoproteins, and insufficient amounts of the healthy fats known as high-density lipoproteins. In addition, they often have high blood pressure and sugar, or glucose, levels.
Previous research has linked metabolic syndrome to testosterone deficiency, which can cause decreased muscle and bone mass, depression, low energy, and decreased sex drive and ability. In addition, testosterone deficiency is also associated with the individual symptoms of metabolic syndrome, even when they are present without the other complications.
"When indicated, testosterone treatment is both essential and safe in elderly patients with symptomatic late onset hypogonadism, or testosterone deficiency," said study lead author Aksam A. Yassin, M.D., Ph.D., Ed.D., chairman of the Institute of Urology & Andrology in Norderstedt-Hamburg, Germany. "Further analysis is needed to confirm if our findings are due to a direct effect of restoring physiologic testosterone levels."
Specifically, investigators found that the prevalence of metabolic syndrome dropped from 56 to 30 percent after 57 months of treatment with testosterone-replacement medication to regulate hormone levels. In addition, triglycerides, and levels of blood sugar and pressure significantly decreased, while the average waist circumference shrank by 11 centimeters.
Beginning in 2004, investigators collected data from 261 patients with late-onset hypogonadism, characterized by both low testosterone levels and sexual dysfunction, at three centers in Germany. Patients received 1,000 milligrams of a long-acting testosterone drug, called undecanoate, on the first day of the study, at week six, and then every three months. At each visit, patients underwent testing of hormone levels, blood-sugar and lipid concentrations, and blood pressure. Average follow-up was four and a quarter years.
"We hypothesized that long-term testosterone improves metabolic syndrome, and found that this intervention improved all three components of obesity, including waist circumference, weight, and body-mass index; diabetes control; poor lipids profile; and blood pressure," Yassin said. To determine the presence of metabolic syndrome among study participants, investigators used the definition from the International Diabetes Federation. Participants were diagnosed with the syndrome if they displayed central-body obesity combined with two other risk factors. These included elevated triglycerides levels, decreased high-density lipoproteins, high blood pressure, and excessive blood-sugar concentrations.

Tuesday, November 27, 2012

Study Shows Estrogen May Prevent Younger Menopausal Women From Strokes

Dr. Enrique Jacome
Estrogen may prevent strokes in premature or early menopausal women, Mayo Clinic researchers say. Their findings challenge the conventional wisdom that estrogen is a risk factor for stroke at all ages. The study was published in the journal Menopause. Researchers combined the results from a recent Mayo Clinic study with six other studies from across the world and found that estrogen is protective for stroke before age 50. That is roughly the average age when women go through menopause.

"We were very surprised because these results were unexpected," says study author Walter Rocca, M.D., an epidemiologist and neurologist at Mayo Clinic. "The old idea that estrogen is always a problem in the brain has to be corrected." Estrogen can be a problem in older women, he explains, but in younger women, estrogen may be important to protect the brain from strokes.

The study has implications for women who experience premature (before age 40) or early menopause (before age 45) from natural causes or from ovary removal. Women in these groups should consider taking estrogen up to approximately age 50 to prevent stroke, Dr. Rocca says.

Ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain. According to the American Stroke Association, these types of strokes account for 87 percent of all stroke cases. If you would like to schedule a hormone evaluation, please contact us at (760) 203-5751 for an appointment.


Co-authors of the study include: Brandon Grossardt, M.S.; Virginia Miller, Ph.D.; Lynne Shuster, M.D.; Robert Brown, Jr., M.D. 

www.vivenaturalhormones.com
 

Friday, November 9, 2012

The Difference Between The Effects Of Bioidentical & Synthetic Hormones On Menopause

Dr. Enrique Jacome
Ever since the Women’s Health Initiative studies came to a screeching halt in 2002, hormone replacement therapy (HRT) has garnered a pretty bad rep. The number of women using HRT declined significantly after it was discovered that the combination of hormones that most women were taking (namely progestin and estrogen) increased the likelihood of heart disease, breast cancer, blood clots and stroke.

The main problem with these studies is that they were only focusing on women who used synthetic hormones, such as Premarin, Provera and Prempro. Nearly a decade later, hormone therapy has become more popular among menopausal women, thanks to natural HRT alternatives, like bioidentical hormone replacement therapy (BHRT).

Bioidentical hormones are molecularly identical to the hormones that the body produces naturally.Bioidentical hormones are derived from naturally occurring, plant-based sources, such as soy and yams. There are several advantages when using natural bioidentical hormones, when compared to their synthetic counterpart.

Being that bioidentical hormones are exact replicas of the hormones your body already produces, the body can’t distinguish the supplemented hormones from the ones your body is producing naturally. So when you take a blood test, your total estradiol level reflects both the bioidentical estradiol and the natural estradiol. This makes it easier for your doctor to closely monitor your total levels and adjust your treatment regimen accordingly. Most synthetic hormones are metabolized differently and aren’t visible using standard lab tests.

Another benefit of using bioidentical hormones is that they’re typically not taken orally. Most synthetic forms of HRT are administered orally, in the form of a pill. Instead, bioidentical hormones are compounded in a laboratory and come in the form of creams, gels, pellets or injection (though not common). It’s best to avoid taking hormones orally (bioidentical or not), because it can lead to high blood pressure, weight gain, elevated cholesterol levels and has even been found to bring on sudden bouts of depression in some women.

Perhaps the most alluring of benefits is the fact that each BHRT regimen is individually tailored to meet your specific needs. There is no such thing as a one-size-fits-all treatment when it comes to balancing hormones. Two women of the same age, who follow the same diet and workout routine, could have wildly different hormone levels. Bioidentical hormones are custom compounded based on your hormone levels and your specific set of symptoms. This makes them far more effective than the synthetic HRT drugs that are currently on the market.